Replaces Prod. #: BML-CT110
Anti-inflammatory and anti-angiogenic agent. Inhibits VEGF-induced angiogenesis in vivo . Inhibits proliferation and tube formation of human endothelial cells in vitro. Also inhibits smooth muscle cell proliferation and prevents post-angiplasty retsenosis.Synthetic compound with structural similarity to the tryptophan (Trp) catabolites kynurenines. Tranilast ameliorates the disease severity in animal models of multiple sclerosis, in part, by inducing T cell tolerance. Trp degradation is an important mechanism in the maintenance of T cell tolerance in a variety of disease models and is mediated by the rate limiting enzyme indoleamine 2,3-dioxygenase (IDO).
Product Details
| Alternative Name: | N-(3’,4’-Dimethoxycinnamoyl)anthranilic acid, 3,4-DAA |
| |
| Formula: | C18H17NO5 |
| |
| MW: | 327.3 |
| |
| CAS: | 53902-12-8 |
| |
| MI: | 14: 9570 |
| |
| RTECS: | DG8731000 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Appearance: | Off-white to yellow solid. |
| |
| Solubility: | Soluble in DMSO. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from light. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Tranilast: a pharmaceutical candidate for reduction of adhesions using a novel approach: J. Petrilli, et al.; Semin. Reprod. Med.
26, 341 (2008),
Abstract;
Anti-inflammatory strategies for the treatment of multiple sclerosis – tryptophan catabolites may hold the key: M. Platten, et al.; Drug Discovery Today
3, 401 (2006),
Abstract;
Tranilast: a novel weapon against insulin resistance: M.R. Namazi & J. Soma; Med. Hypotheses
64, 1135 (2005),
Abstract;
Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite: M. Platten, et al.; Science
310, 850 (2005),
Abstract;
Tranilast inhibits cytokine-induced nuclear factor kappaB activation in vascular endothelial cells: M. Spiecker, et al.; Mol. Pharmacol.
62, 856 (2002),
Abstract;
Full Text
Tranilast inhibits interleukin-1beta-induced monocyte chemoattractant protein-1 expression in rat mesangial cells: A. Chikaraishi, et al.; Eur. J. Pharmacol.
427, 151 (2001),
Abstract;
Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21(waf1/cip1/sdi1) and p53: A. Takahashi et al.; Circ Res
84, 543 (1999),
Abstract;
Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo: M. Isaji et al.; Br. J. Pharmacol.
122, 1061 (1997),
Abstract;
Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts: H. Yamada, et al.; J. Biochem.
116, 892 (1994),
Abstract;
Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages: H. Suzawa, et al.; Jpn. J. Pharmacol.
60, 85 (1992),
Abstract;
